title: Clinico-pathological characteristics of p63 expression in B-cell lymphoma.
abstract: A member of the family of p53-related genes, p63 plays a role in regulating epithelial proliferation and differentiation programs, but the pathological and clinical meaning of p63 in B-cell lymphoma has not been elucidated. We investigated the expression pattern of p63 in B-cell malignancies, and evaluated the correlation between the expression of p63 and other germinal center markers. Ninety-eight B-cell lymphomas (28 FCL, 5 MCL, and 65 DLBCL) were analyzed by immunohistochemical examination for p63, bcl-6, CD10 and MUM-1 proteins, and for rearrangement of bcl-2/IgH. Expression of p63 was observed in the nuclei of tumor cells obtained from 15 of 28 (54%) FCL, 22 of 65 (34%) DLBCL, but none of 5 MCL. In DLBCL, the expression of p63 and bcl-6 showed a significant correlation (P < 0.02), but no correlation was observed between p63 and expression of CD10, MUM-1, or bcl-2/IgH rearrangement. RT-PCR revealed that TAp63alpha-type transcripts, a possible negative regulator of transcriptional activation of p21 promoter, were major transcripts in B-cell lymphoma tissues. As for prognostic significance, only patients in the p63 positive group of FCL died, and in the non-germinal center group, the p63 positive cases appeared to have inferior overall survival than other groups in DLBCL. Our preliminary results suggested that p63 expression is a disadvantageous factor for prognosis in this subgroup of B-cell lymphomas.
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, Saga University, Saga-City, Saga, Japan. fukushin@cc.saga-u.ac.jp
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Fukushima
authors.forename: Toshimi
authors.initials: T
authors.lastname: Satoh
authors.forename: Naoko
authors.initials: N
authors.lastname: Sueoka
authors.forename: Akemi
authors.initials: A
authors.lastname: Sato
authors.forename: Masaru
authors.initials: M
authors.lastname: Ide
authors.forename: Takashi
authors.initials: T
authors.lastname: Hisatomi
authors.forename: Nobuo
authors.initials: N
authors.lastname: Kuwahara
authors.forename: Rika
authors.initials: R
authors.lastname: Tomimasu
authors.forename: Naoko
authors.initials: N
authors.lastname: Tsuneyoshi
authors.forename: Noriko
authors.initials: N
authors.lastname: Funai
authors.forename: Masayuki
authors.initials: M
authors.lastname: Sano
authors.forename: Osamu
authors.initials: O
authors.lastname: Tokunaga
authors.forename: Eisaburo
authors.initials: E
authors.lastname: Sueoka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017398:Alternative Splicing; D004268:DNA-Binding Proteins / Q000032:analysis* / Q000235:genetics; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D015534:Trans-Activators / Q000032:analysis* / Q000235:genetics; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins / Q000032:analysis* / Q000235:genetics
chemical_list: D004268:DNA-Binding Proteins; D012333:RNA, Messenger; C115051:TP63 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins